🔎 Trials Near Me

Beranda › Obesitas › Indiana › Indianapolis

Uji klinis Obesitas di Indianapolis, IN

20 studi untuk Obesitas mencari peserta di lokasi sekitar Indianapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Menerima pesertaFase 2
  • Franciscan Physician Network - Indiana Heart Physicians, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07783802

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Menerima pesertaFase 3
  • IU Health - Riley Physicians Endo-Diab, Indianapolis
Usia 8 hingga 18 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07253285

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Menerima pesertaFase 3
  • Midwest Inst For Clin Res, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Menerima pesertaFase 3
  • Midwest Inst For Clin Res, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07668414

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Menerima pesertaFase 3
  • Indiana University Health University Hospital, Indianapolis
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Menerima pesertaFase 3
  • Riley Hospital for Children, Indianapolis
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Menerima pesertaFase 3
  • Indiana University Health University Hospital, Indianapolis
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Menerima pesertaFase 3
  • Midwest Inst For Clin Res, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07339423

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Menerima pesertaFase 3
  • DM Clinical Research - Indianapolis, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07282600

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Menerima pesertaFase 3
  • AURORA-1 Clinical Site, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Menerima pesertaFase 3
  • AURORA-2 Clinical Site, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Menerima pesertaFase 3
  • Ascension Medical Group, Indianapolis
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Menerima pesertaFase 2
  • Investigators Research Group, Brownsburg · 14 mi jauhnya
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06897475

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Menerima pesertaFase 4
  • Dawes Fretzin Clinical Research Group, LLC, Indianapolis
  • The Indiana Clinical Trials Center, PC, Plainfield · 14 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06857942

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Menerima pesertaFase 3
  • Midwest Inst For Clin Res, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07745504

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Menerima pesertaFase 2
  • Indiana University School of Medicine, Indianapolis
Usia 11 hingga 18 · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT05414409

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Menerima pesertaFase 3
  • Indiana University Health Methodist Hospital, Indianapolis
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

Menerima pesertaSukarelawan sehat diterima
  • Indiana University Hospital, Indianapolis
Usia 12 hingga 18 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07223151

Fibrosis Lessens After Metabolic Surgery

Menerima pesertaFase 4Sukarelawan sehat diterima
  • Indiana University, Indianapolis
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06374875

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

Menerima peserta
  • Indiana University, Indianapolis
Usia 18 hingga 45 · Wanita · Diperbarui 24 Jun 2026 · NCT05124808

Uji klinis Obesitas di kota lain

Studi lain di Indianapolis

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.